Objectives: To measure olfactory bulbs and sulci using dedicated magnetic resonance imaging (MRI) sequences and specific measurement tools in Kallmann syndrome (KS) patients with a well-established genotype and phenotype, as well as correlate MRI findings with a clinical smell test. Methods: MRI was performed in 21 patients with KS and 16 healthy volunteers; olfactory dysfunction was assessed using the Smell Identification Test (UPSIT), a qualitative suprathreshold olfaction test. Coronal turbo spin echo T2-weighted and volumetric T1-weighted gradient echo sequences were acquired in a 1.5T system. ImageJ software was used to obtain olfactory bulb volumes and olfactory sulcus depths and lengths. Data were analyzed with SPSS 15.0 and the Kappa index was used to evaluate the agreement between the UPSIT and MRI. Results: The UPSIT showed 14 patients with anosmia and 6 with moderate hyposmia. Eighteen patients (85%) presented altered rhinencephalon structures in the MRI. Sixteen patients (76%) presented olfactory bulb aplasia (14/16 bilaterally), and these patients presented a total of 16 aplastic sulci. There was moderate agreement between the MRI quantitative evaluation and the UPSIT (overall Kappa = 0.55), but when considering the presence of aplastic bulbs and anosmia, we found almost perfect agreement (Kappa = 0.87). Three patients had normal rhinencephalon structures, including one with a KAL1 gene mutation. Conclusion: Olfactory bulb and sulcus aplasia were the most common findings in KS patients. We objectively demonstrated agreement between MRI findings and the smell test, especially the presence of bulb aplasia and anosmia. Therefore, our findings help ascertain MRI accuracy in the diagnosis of KS, differentiating patients with hypogonadotropic hypogonadism with an apparently normal or difficult to evaluate sense of smell.

Keywords:
Kallmann syndrome, Olfactory structures, Magnetic resonance imaging, Smell test
1.
Kalmann FJ, Schonfeld WA, Barrera SA: The genetic aspects of primary eunuchoidism. Am J Ment Defic 1944;48:203–236.
2.
Maestre de San Juan A: Teratolagia: falta total de los nervios olfactorios con anosmia en un individuo en quien existia una atrofia congenita de los testiculos y miembro viril. El Siglo Medico 1856;3:211–221.
3.
Seminara SB, Hayes FJ, Crowley WF Jr: Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann’s syndrome): pathophysiological and genetic considerations. Endocr Rev 1998;19:521–539.
4.
Ribeiro RS, Abucham J: Kallmann syndrome: a hystorical, clinical and molecular review (in Portuguese). Arq Bras Endocrinol Metabol 2008;52:8–17.
5.
Dode C, Hardelin JP: Kallmann syndrome. Eur J Hum Genet 2009;17:139–146.
6.
Legouis R, Hardelin JP, Levilliers J, Claverie JM, Compain S, Wunderle V, Millasseau P, Le Paslier D, Cohen D, Caterina D, Bougueleret L, Delemarre-Van de Waal H, Lutfalla G, Weissenbach J, Petit C: The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. Cell 1991;67:423–435.
7.
Franco B, Guioli S, Pragliola A, Incerti B, Bardoni B, Tonlorenzi R, Carrozzo R, Maestrini E, Pieretti M, Taillon-Miller P, Brown CJ, Willard HF, Lawrence C, Persico MG, Camerino G, Ballabio A: A gene deleted in Kallmann’s syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature 1991;353:529–536.
8.
Dode C, Levilliers J, Dupont JM, De Paepe A, Le Du N, Soussi-Yanicostas N, Coimbra RS, Delmaghani S, Compain-Nouaille S, Baverel F, Pecheux C, Le Tessier D, Cruaud C, Delpech M, Speleman F, Vermeulen S, Amalfitano A, Bachelot Y, Bouchard P, Cabrol S, Carel JC, Delemarre-van de Waal H, Goulet-Salmon B, Kottler ML, Richard O, Sanchez-Franco F, Saura R, Young J, Petit C, Hardelin JP: Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 2003;33:463–465.
9.
Dode C, Teixeira L, Levilliers J, Fouveaut C, Bouchard P, Kottler ML, Lespinasse J, Lienhardt-Roussie A, Mathieu M, Moerman A, Morgan G, Murat A, Toublanc JE, Wolczynski S, Delpech M, Petit C, Young J, Hardelin JP: Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet 2006;2:e175.
10.
Abreu AP, Trarbach EB, de Castro M, Frade Costa EM, Versiani B, Matias Baptista MT, Garmes HM, Mendonca BB, Latronico AC: Loss-of-function mutations in the genes encoding prokineticin-2 or prokineticin receptor-2 cause autosomal recessive Kallmann syndrome. J Clin Endocrinol Metab 2008;93:4113–4118.
11.
Sarfati J, Guiochon-Mantel A, Rondard P, Arnulf I, Garcia-Pinero A, Wolczynski S, Brailly-Tabard S, Bidet M, Ramos-Arroyo M, Mathieu M, Lienhardt-Roussie A, Morgan G, Turki Z, Bremont C, Lespinasse J, Du Boullay H, Chabbert-Buffet N, Jacquemont S, Reach G, De Talence N, Tonella P, Conrad B, Despert F, Delobel B, Brue T, Bouvattier C, Cabrol S, Pugeat M, Murat A, Bouchard P, Hardelin JP, Dode C, Young J: A comparative phenotypic study of Kallmann syndrome patients carrying monoallelic and biallelic mutations in the prokineticin 2 or prokineticin receptor 2 genes. J Clin Endocrinol Metab 2010;95:659–669.
12.
Pitteloud N, Zhang C, Pignatelli D, Li JD, Raivio T, Cole LW, Plummer L, Jacobson-Dickman EE, Mellon PL, Zhou QY, Crowley WF Jr: Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 2007;104:17447–17452.
13.
Falardeau J, Chung WC, Beenken A, Raivio T, Plummer L, Sidis Y, Jacobson-Dickman EE, Eliseenkova AV, Ma J, Dwyer A, Quinton R, Na S, Hall JE, Huot C, Alois N, Pearce SH, Cole LW, Hughes V, Mohammadi M, Tsai P, Pitteloud N: Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest 2008;118:2822–2831.
14.
Kim HG, Kurth I, Lan F, Meliciani I, Wenzel W, Eom SH, Kang GB, Rosenberger G, Tekin M, Ozata M, Bick DP, Sherins RJ, Walker SL, Shi Y, Gusella JF, Layman LC: Mutations in CHD7, encoding a chromatin-remodeling protein, cause idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. Am J Hum Genet 2008;83:511–519.
15.
Doty RL, Shaman P, Dann M: Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 1984;32:489–502.
16.
Davidson TM, Murphy C: Rapid clinical evaluation of anosmia. The alcohol sniff test. Arch Otolaryngol Head Neck Surg 1997;123:591–594.
17.
Eloit C, Trotier D: A new clinical olfactory test to quantify olfactory deficiencies. Rhinology 1994;32:57–61.
18.
Lieblich JM, Rogol AD, White BJ, Rosen SW: Syndrome of anosmia with hypogonadotropic hypogonadism (Kallmann syndrome): clinical and laboratory studies in 23 cases. Am J Med 1982;73:506–519.
19.
Klingmuller D, Dewes W, Krahe T, Brecht G, Schweikert HU: Magnetic resonance imaging of the brain in patients with anosmia and hypothalamic hypogonadism (Kallmann’s syndrome). J Clin Endocrinol Metab 1987;65:581–584.
20.
Bajaj S, Ammini AC, Marwaha R, Gulati P, Khetarpal K, Mahajan H: Magnetic resonance imaging of the brain in idiopathic hypogonadotropic hypogonadism. Clin Radiol 1993;48:122–124.
21.
Yousem DM, Turner WJ, Li C, Snyder PJ, Doty RL: Kallmann syndrome: MR evaluation of olfactory system. AJNR Am J Neuroradiol 1993;14:839–843.
22.
Truwit CL, Barkovich AJ, Grumbach MM, Martini JJ: MR imaging of Kallmann syndrome, a genetic disorder of neuronal migration affecting the olfactory and genital systems. AJNR Am J Neuroradiol 1993;14:827–838.
23.
Knorr JR, Ragland RL, Brown RS, Gelber N: Kallmann syndrome: MR findings. AJNR Am J Neuroradiol 1993;14:845–851.
24.
Vogl TJ, Stemmler J, Heye B, Schopohl J, Danek A, Bergman C, Balzer JO, Felix R: Kallman syndrome versus idiopathic hypogonadotropic hypogonadism at MR imaging. Radiology 1994;191:53–57.
25.
Yousem DM, Geckle RJ, Bilker W, McKeown DA, Doty RL: MR evaluation of patients with congenital hyposmia or anosmia. AJR Am J Roentgenol 1996;166:439–443.
26.
Abolmaali ND, Hietschold V, Vogl TJ, Huttenbrink KB, Hummel T: MR evaluation in patients with isolated anosmia since birth or early childhood. AJNR Am J Neuroradiol 2002;23:157–164.
27.
Versiani BR, Trarbach E, Koenigkam-Santos M, Dos Santos AC, Elias LL, Moreira AC, Latronico AC, de Castro M: Clinical assessment and molecular analysis of GnRHR and KAL1 genes in males with idiopathic hypogonadotrophic hypogonadism. Clin Endocrinol (Oxf) 2007;66:173–179.
28.
Trarbach EB, Costa EM, Versiani B, de Castro M, Baptista MT, Garmes HM, de Mendonca BB, Latronico AC: Novel fibroblast growth factor receptor 1 mutations in patients with congenital hypogonadotropic hypogonadism with and without anosmia. J Clin Endocrinol Metab 2006;91:4006–4012.
29.
Koenigkam-Santos M, Santos AC, Borduqui T, Versiani BR, Hallak JE, Crippa JA, Castro M: Whole-brain voxel-based morphometry in Kallmann syndrome associated with mirror movements. AJNR Am J Neuroradiol 2008;29:1799–1804.
30.
Koenigkam-Santos M, de Castro M, Versiani BR, Diniz PR, Santos AC: Kallmann syndrome and mirror movements: white matter quantitative evaluation with magnetic resonance imaging. J Neurol Sci 2010;292:40–44.
31.
Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977;33:159–174.
32.
Quinton R, Duke VM, de Zoysa PA, Platts AD, Valentine A, Kendall B, Pickman S, Kirk JM, Besser GM, Jacobs HS, Bouloux PM: The neuroradiology of Kallmann’s syndrome: a genotypic and phenotypic analysis. J Clin Endocrinol Metab 1996;81:3010–3017.
33.
Fuerxer F, Carlier R, Iffenecker C, Schaison G, Doyon D: Magnetic resonance imaging of the olfactory pathways in Kallmann de Morsier syndrome (in French). J Neuroradiol 1996;23:223–230.
34.
Madan R, Sawlani V, Gupta S, Phadke RV: MRI findings in Kallmann syndrome. Neurol India 2004;52:501–503.
35.
Sato N, Katsumata N, Kagami M, Hasegawa T, Hori N, Kawakita S, Minowada S, Shimotsuka A, Shishiba Y, Yokozawa M, Yasuda T, Nagasaki K, Hasegawa D, Hasegawa Y, Tachibana K, Naiki Y, Horikawa R, Tanaka T, Ogata T: Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients. J Clin Endocrinol Metab 2004;89:1079–1088.
36.
Riedl S, Vosahlo J, Battelino T, Stirn-Kranjc B, Brugger PC, Prayer D, Mullner-Eidenbock A, Kapelari K, Blumel P, Waldhor T, Krasny J, Lebl J, Frisch H: Refining clinical phenotypes in septo-optic dysplasia based on MRI findings. Eur J Pediatr 2008;167:1269–1276.
37.
de m Freitas P, Carvalho S, Ribeiro F, Marnoto D, Martins F: Neuroradiology of Kallmann’s syndrome. Acta Med Port 2001;14:123–126.
38.
Heine O, Galaburda AM: Olfactory asymmetry in the rat brain. Exp Neurol 1986;91:392–398.
39.
Doty RL: Studies of human olfaction from the University of Pennsylvania Smell and Taste Center. Chem Senses 1997;22:565–586.
40.
Silveira-Moriyama L, Azevedo AMS, Ranvaud R, Barbosa ER, Doty RL, Lees AJ: Applying a new version of the Brazilian-Portuguese UPSIT smell test in Brazil. Arq Neuropsiquiatr 2010;68:700–705.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.